Syndax Pharmaceuticals Inc (NASDAQ: SNDX) kicked off on Friday, down -1.11% from the previous trading day, before settling in for the closing price of $14.41. Over the past 52 weeks, SNDX has traded in a range of $12.06-$25.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 2252.39% over the last five years. While this was happening, its average annual earnings per share was recorded -16.86%. With a float of $81.08 million, this company’s outstanding shares have now reached $85.57 million.
The firm has a total of 184 workers. Let’s measure their productivity. In terms of profitability, gross margin is -169.78%, operating margin of -1942.5%, and the pretax margin is -1796.46%.
Syndax Pharmaceuticals Inc (SNDX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Syndax Pharmaceuticals Inc is 5.02%, while institutional ownership is 104.07%. The most recent insider transaction that took place on Jun 14 ’24, was worth 25,037. In this transaction Chief Financial Officer of this company bought 1,250 shares at a rate of $20.03, taking the stock ownership to the 52,623 shares.
Syndax Pharmaceuticals Inc (SNDX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.79% during the next five years compared to -0.41% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Take a look at Syndax Pharmaceuticals Inc’s (SNDX) current performance indicators. Last quarter, stock had a quick ratio of 6.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 76.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.63, a number that is poised to hit -0.85 in the next quarter and is forecasted to reach -3.85 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Analysing the last 5-days average volume posted by the [Syndax Pharmaceuticals Inc, SNDX], we can find that recorded value of 2.0 million was better than the volume posted last year of 1.94 million. As of the previous 9 days, the stock’s Stochastic %D was 91.78%. Additionally, its Average True Range was 0.73.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 20.98%, which indicates a significant decrease from 82.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.15% in the past 14 days, which was lower than the 64.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.75, while its 200-day Moving Average is $19.00. Now, the first resistance to watch is $14.68. This is followed by the second major resistance level at $15.12. The third major resistance level sits at $15.50. If the price goes on to break the first support level at $13.86, it is likely to go to the next support level at $13.48. Should the price break the second support level, the third support level stands at $13.04.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
The company with the Market Capitalisation of 1.22 billion has total of 85,358K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -209,360 K annual income. Company’s last quarter sales were recorded 12,500 K and last quarter income was -84,130 K.
